September 30, 2025

PRECISEU Best Practice Recognition 2025: Celebrating Europe’s Leaders in Personalised Medicine

PRECISEU Best Practice Recognition 2025: Celebrating Europe’s Leaders in Personalised Medicine

Vilnius, 18 September 2025

The PRECISEU consortium proudly announced the winners of the first PRECISEU Best Practice Recognition during Life Sciences Baltics 2025, the leading international event for biotechnology, pharmaceuticals, and medical devices in the Baltic region.

Launched under the Personalised Medicine Empowerment Connecting Innovation ecoSystems across EUROPE (PRECISEU) programme, this initiative honours outstanding practices in personalised medicine and advanced therapies.

It was the perfect opportunity to celebrate projects that pair innovation with inclusivity and real-world impact, turning cutting-edge science into tangible healthcare solutions.

From 68 applications across Europe, four winners were selected by an expert jury, representing excellence in Impact, Innovation, Excellence, and Culture.

Subtitle: The 2025 PRECISEU Best Practice Recognition Winners

IMPACT – DIPCAN (Genomcore, S.L.)

From Insight to Intervention

DIPCAN, powered by GENOMCORE BIMS, accelerates Europe’s ATMP innovation by enabling EHDS-compliant federated data sharing, advanced multimodal AI analytics, and ensuring regulatory trust, driving faster personalized clinical breakthroughs.

Jury statement: “DIPCAN is a project of outstanding quality across nearly all evaluation areas”;  ”The DIPCAN project effectively illustrates the translation of a sophisticated data infrastructure into measurable clinical and research outcomes at a national level.”

Team: Miquel A. Bru (Genomcore, S.L.)

INNOVATION – OPORA Health

Pushing the Boundaries of What’s Possible

OPORA Health is an AI-ready platform for secure, multimodal brain health data, supporting PTSD care and research in war-affected populations across Ukraine, the UK, and Europe.

Jury statement: “very relevant unmet health need”; ” this project is excellent [..] because it comprehensively matches all criteria of the call”

Team: Daria Volkova, Svitlana Surodina and Yegor Cotov

EXCELLENCE – PragmaTIL (Vall d’Hebron Institute of Oncology)

Harnessing the Power of Data

The PragmaTIL trial aims to optimize TIL-ACT for cancer and enhance its clinical use in academic hospitals.

Jury statement: “[PragmaTIL] has an original concept of decentralized patient care with ATMPs leading to great sustainability”; ”innovative approach to decentralize manufacturing across different countries within a clinical trial”

Team: Silvia Martín Lluesma, Elena Garralda, Alena Gros (Vall d’Hebron Institute of Oncology-VHIO) and Inés Vaz-Luis (Goustave Roussy)

CULTURE – ENGAGE-ATMP (Sant Joan de Déu Barcelona Children’s Hospital)

Building Trust and Engagement

ENGAGE-ATMP is an innovative, patient-centric translational model for ATMP research and healthcare, to provide holistic, accessible care while empowering patients and caregivers to actively participate in the process.

Jury statement:  “Excellent patient-centered methods and perspective”; ”[ENGAGE-ATMP] represents a benchmark in cultural transformation around patient engagement in ATMP research and care. Its long-standing, institutionalized approach demonstrates maturity, inclusivity, and real-world impact, particularly in pediatric rare disease contexts.”

Team: Alessandra Magnani (Fundació Privada Recerca i Docència Sant Joan de Déu, FSJD-CERCA), Joan Vinyets Rejon (Hospital Sant Joan de Déu, HSJD), Begonya Nafria Escalera (FSJD-CERCA) 

Subtitle:  A milestone for PRECISEU

The awards ceremony took place alongside the PRECISEU General Assembly, where partners reviewed achievements to date and set the Year 2 Action Plan. Together, these activities mark a key milestone in PRECISEU’s mission: strengthening Europe’s capacity to deliver the promise of personalised medicine.

Subtitle: About PRECISEU

PRECISEU is a Horizon Europe project working to connect innovation ecosystems and accelerate the adoption of personalised medicine across Europe, with a strong focus on health data, advanced therapies, and patient engagement. Learn more at www.preciseu.eu.

Subtitle: About Life Sciences Baltics

Life Sciences Baltics is the premier international forum in the Baltics for experts in biotechnology, pharmaceuticals, and medical devices to connect, exchange knowledge, and showcase cutting-edge innovation. More at lifesciencesbaltics.com.

Our latest News

discover more
One device – two organs: Simultaneous perfusion opens up new possibilities for future multi-organ transplants

One device – two organs: Simultaneous perfusion opens up new possibilities for future multi-organ transplants

A key factor in the success of an organ transplant is the condition of the donated organ at the time of implantation. Preserving the organ prior to transplantation using machine perfusion plays a crucial role in this process. This procedure has now been implemented particularly efficiently at Heidelberg University Hospital (UKHD): as part of a […]

Award-winning: Concept for “the perfect stroke room”

Award-winning: Concept for “the perfect stroke room”

UKHD wins DGN Nursing Award 2025 for its “Stroke Unit Innovation Room” project. Full Text in German below. Ausgezeichnet: Konzept für „das perfekte Schlaganfallzimmer“ UKHD gewinnt DGN-Pflegepreis 2025 für das Projekt „Innovationszimmer Stroke Unit“ Das Universitätsklinikum Heidelberg (UKHD) ist mit dem Pflegepreis der Deutschen Gesellschaft für Neurologie (DGN) ausgezeichnet worden. Prämiert wurde das Projekt „Innovationszimmer […]

FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer

FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer

Promega’s MSI technology will help identify patients with microsatellite stable (MSS) endometrial cancer Full Text in German below. Die FDA genehmigt das Promega OncoMate® MSI Dx Analysis System als Begleitdiagnostikum für KEYTRUDA® in Kombination mit LENVIMA® bei fortgeschrittenem Endometriumkarzinom  Die MSI-Technologie von Promega wird bei der Identifizierung von Patientinnen mit mikrosatellitenstabilem (MSS) Endometriumkarzinom helfen Madison, […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp